Koch, Tobias
Lenz, Tobias
Joner, Michael
Xhepa, Erion
Koppara, Tobias
Wiebe, Jens
Coughlan, J. J.
Aytekin, Alp
Ibrahim, Tareq
Kessler, Thorsten
Cassese, Salvatore
Laugwitz, Karl-Ludwig
Schunkert, Heribert
Kastrati, Adnan
Kufner, Sebastian http://orcid.org/0000-0002-8091-4552
Mehilli, Julinda
Hausleiter, Jörg
Kastrati, Adnan
Byrne, Robert A.
Ibrahim, Tareq
Laugwitz, Karl-Ludwig
Schunkert, Heribert
Kufner, Sebastian
,
Funding for this research was provided by:
Bayerische Forschungsstiftung (BFS-ISAR Aktenzeichen AZ: 504/02 and BFS-DES Aktenzeichen AZ: 668/05))
FP7 Health (FP7 PRESTIGE 260309)
Deutsches Herzzentrum München
Article History
Received: 18 February 2021
Accepted: 7 April 2021
First Online: 22 June 2021
Declarations
:
: MJ reports speaker fees from Biotronik, Boston Scientific, AstraZeneca, Coramaze, and OrbusNeich, as well as research grants from Biotronik and the European Society of Cardiology; JW reports minor speaker fees from Astra Zeneca; HS reports honoraria fees from AstraZeneca, Bayer Vital, MSD SHARP&DOHME, Novartis, Servier, Sanofi-Aventis, Boehringer Ingelheim, Daiichi Sankyo, Amgen, Pfizer and consulting fees from AstraZeneca, Amgen, MSD SHARP&DOHME; SK reports speaker fees from Astra Zeneca, speaker and consulting fees from Bristol Myers Squibb and speaker and consulting fees from Translumina, all other authors report no conflict of interest.
: The trial protocol was approved by the institutional ethics committee of the two participating centers: Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, both in Munich, Germany.